272.62
11.99 (4.60%)
| Previous Close | 260.63 |
| Open | 268.19 |
| Volume | 307,491 |
| Avg. Volume (3M) | 467,750 |
| Market Cap | 10,500,204,544 |
| Price / Earnings (TTM) | 778.91 |
| Price / Earnings (Forward) | 83.33 |
| Price / Sales | 9.39 |
| Price / Book | 9.48 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | 3.41% |
| Operating Margin (TTM) | 12.45% |
| Diluted EPS (TTM) | 1.08 |
| Quarterly Revenue Growth (YOY) | 16.30% |
| Quarterly Earnings Growth (YOY) | 256.50% |
| Total Debt/Equity (MRQ) | 18.19% |
| Current Ratio (MRQ) | 6.30 |
| Operating Cash Flow (TTM) | 179.16 M |
| Levered Free Cash Flow (TTM) | 135.83 M |
| Return on Assets (TTM) | 5.82% |
| Return on Equity (TTM) | 3.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | Penumbra, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.46% |
| % Held by Institutions | 91.80% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 330.00 (RBC Capital, 21.05%) | Buy |
| 330.00 (UBS, 21.05%) | Buy | |
| 330.00 (Truist Securities, 21.05%) | Buy | |
| Median | 325.00 (19.21%) | |
| Low | 315.00 (Wells Fargo, 15.55%) | Buy |
| Average | 324.00 (18.85%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 294.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 24 Apr 2025 | 325.00 (19.21%) | Buy | 298.25 |
| RBC Capital | 24 Apr 2025 | 330.00 (21.05%) | Buy | 298.25 |
| Stifel | 24 Apr 2025 | 318.00 (16.65%) | Buy | 298.25 |
| Truist Securities | 24 Apr 2025 | 330.00 (21.05%) | Buy | 298.25 |
| 11 Apr 2025 | 315.00 (15.55%) | Buy | 272.32 | |
| UBS | 24 Apr 2025 | 330.00 (21.05%) | Buy | 298.25 |
| Wells Fargo | 24 Apr 2025 | 315.00 (15.55%) | Buy | 298.25 |
| B of A Securities | 14 Mar 2025 | 320.00 (17.38%) | Buy | 272.62 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 May 2025 | Announcement | Penumbra, Inc. to Present at Upcoming Investor Conferences |
| 29 Apr 2025 | Announcement | Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference |
| 23 Apr 2025 | Announcement | Penumbra, Inc. Reports First Quarter 2025 Financial Results |
| 03 Apr 2025 | Announcement | Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 |
| 02 Apr 2025 | Announcement | Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |